3)

2)

Of all my tweets on taking care of patients, here are 3 personal favorites. #MedTwitter

1)

Our one stop website for myeloma risk:

-MM risk stratification
-SMM risk stratification
-MGUS risk stratification
-AL amyloid risk stratification

New:
-IFM Frailty score
-Waldenstrom prognosis
- iSTOP MM guide for marrow in MGUS

MyelomaRisk.com

eatoure.github.io

Clinical outcomes of patients with lymphoid blastic phase of chronic myeloid leukemia treated with CAR T-cell therapy Blood Cancer Journal
nature.com/articles/s4140…

Reducing and controlling metabolic active tumor volume prior to CAR T-cell infusion can improve survival outcomes in patients with large B-cell lymphoma Blood Cancer Journal
nature.com/articles/s4140…

Momelotinib for myelofibrosis: our 14 years of experience with 100 clinical trial patients and recent FDA approval Blood Cancer Journal
nature.com/articles/s4140…

Treatment-emergent mutations in myelodysplastic syndrome with del(5q) – lenalidomide related or disease-intrinsic clonal evolution? Blood Cancer Journal
nature.com/articles/s4140…

Much progress done in #AML over 50 yrs. #Ven effects may need few more yrs to show impact in elderly pts who did not change much
⁦⁦Blood Cancer Journal⁩

Age-specific survival in acute myeloid leukemia in the Nordic countries through a half century | nature.com/articles/s4140…

1/ Congrats Fieke Hoff Gurbakhash Kaur et al!

Do you dose bortezomib 2x weekly in myeloma #MMsm because you feel beholden to verbatim trial regimens?

Time to stop!

In our analysis of ~2500 pts,
🛑 2x as much neuropathy
🛑 2x as much time in clinic
🛑 Your peers are stopping too

2/ Certainly, it'd be reasonable to discuss an #MMsm strategy with more neuropathy & time toxicity if we thought it'd improve outcomes.

But biggest red flag 🚩: 2x weekly bortezomib has no advantages in PFS or OS over 1x weekly dosing.

🚮 Drop the Day 4 and 11 doses today!

Happy to share our publication showing that 2-weekly bortezomib is still given in >25% of all ND patients with multiple myeloma despite similar OS and PFS and higher neuropathy rates as 1-weekly administration! Gurbakhash Kaur Rahul Banerjee, MD, FACP Blood Cancer Journal
nature.com/articles/s4140…

#Momelotinib for #myelofibrosis : our 14 years of experience with 100 clinical trial patients and recent FDA approval
nature.com/articles/s4140…
Blood Cancer Journal MPN_Hub MPN Research Foundation #MPNsm

I'm really pleased to share our latest manuscript in Blood Cancer Journal: nature.com/articles/s4140…

Bayesian analysis might be considered to expedite clinical trial adaptation and enhance efficiency in drug development.

Thanks to all collaborators!
Jurjen Versluis #HOVON #Bayesian

With Dr. Kyle (center) and Morie Gertz

Thanks to Shaji Kumar for taking the picture! Mayo Clinic

Large differencies in age-specific survival in multiple myeloma in the nordic countries.

#Myeloma #CancerAwareness #CancerResearch #BloodCancerJournal

Blood Cancer Journal Blood Cancer UK Research Lymphoma, Leukemia & Myeloma Congress Sanofi Myeloma Canadian Cancer Society Cancer Research UK

nature.com/articles/s4140…

Breaking: ODAC votes 11-0 to recommend approval of ciltacel in patients with relapsed/refractory multiple myeloma in earlier stages.

I’m glad. Right call. But we need to be careful. Read on.

cancernetwork.com/view/odac-cast…

Our #TRBC2 #flow paper is out 🎉🎇🙌

Brilliant collaborative effort from Mayo Clinic #hemepath , UCL, Autolus, & U. of Cologne, led by Dr. Horna!

nature.com/articles/s4140…

Mayo Clinic Labs Mayo ClinicPath Ameet Kini, MD, PhD ICCS_Education Blood Cancer Journal Vincent Rajkumar

Our multi-center study [n=110] on outcomes with teclistamab outside of clinical trials led by Meera Mohan!
Blood Cancer Journal

76% Penta-refractory
35% w prior BCMA Rx

≥VGPR: 51%
Grade ≥3 CRS; ICANS: 3.5%; 4.6%

Primary IVIG ppx⬇️risk of G≥3 infections!…

Study on AEs and NRM of BCMA directed therapy from the FAERS database.
led by Zimu Gong
Blood Cancer Journal
Infections complications with Teclistamab >>> ide-cel & cilta-cel
Teclistamab - highest OR for NRM compared to ide-cel & cilta-cel
nature.com/articles/s4140…
MCW Cancer Center